Paxalisib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Paxalisib
- DrugBank Accession Number
- DB15186
- Background
GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 382.428
Monoisotopic: 382.18657198 - Chemical Formula
- C18H22N8O2
- Synonyms
- 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine
- External IDs
- G-02441729
- G02441729
- GDC-0084
- GDC0084
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P5DKZ70636
- CAS number
- 1382979-44-3
- InChI Key
- LGWACEZVCMBSKW-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
- IUPAC Name
- 5-[6,6-dimethyl-4-(morpholin-4-yl)-6H,8H,9H-[1,4]oxazino[3,4-h]purin-2-yl]pyrimidin-2-amine
- SMILES
- CC1(C)OCCN2C1=NC1=C(N=C(N=C21)C1=CN=C(N)N=C1)N1CCOCC1
References
- General References
- Not Available
- External Links
- ChemSpider
- 57251291
- BindingDB
- 50177662
- ChEMBL
- CHEMBL3813842
- ZINC
- ZINC000149645112
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Adult Glioblastoma 1 2 Active Not Recruiting Treatment Diffuse Intrinsic Pontine Gliomas (DIPG) / Diffuse Midline Glioma, H3 K27M-Mutant / Recurrent Diffuse Intrinsic Pontine Glioma / Recurrent Diffuse Midline Glioma, H3 K27M-Mutant / Recurrent WHO Grade III Glioma / WHO Grade 3 Glioma 1 2 Recruiting Treatment Brain Metastases / CDK Gene Mutation / KRAS G12C Mutation / Metastatic Malignant Solid Neoplasms / NTRK Family Gene Mutation / PI3K Gene Mutation / ROS1 Gene Mutation 1 2 Recruiting Treatment Breast Cancer 1 2 Recruiting Treatment High Grade Glioma: Glioblastoma (GBM) 1 2 Recruiting Treatment Non-Hodgkin Lymphoma of Extranodal Site / Primary Central Nervous System Lymphoma 1 2, 3 Recruiting Treatment High Grade Glioma: Glioblastoma (GBM) 1 1 Active Not Recruiting Treatment Healthy Subjects (HS) 1 1 Completed Treatment Brain and Central Nervous System Tumors 1 1 Completed Treatment Glioblastoma, Glioma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.993 mg/mL ALOGPS logP 1.62 ALOGPS logP 1.32 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 15.83 Chemaxon pKa (Strongest Basic) 3.98 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 117.1 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 115.15 m3·mol-1 Chemaxon Polarizability 40.86 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:57 / Updated at December 01, 2022 11:29